Supernus 製藥公司
US ˙ NasdaqGM ˙ US8684591089

SecuritySUPN / Supernus Pharmaceuticals, Inc.
InstitutionMorgan Stanley
Latest Disclosed Ownership913,893 shares
Latest Disclosed Value $ 47,239,157
Morgan Stanley reports 15.34% decrease in ownership of SUPN / Supernus Pharmaceuticals, Inc.

On May 15, 2026 - Morgan Stanley filed a 13F-HR form disclosing ownership of 913,893 shares of Supernus Pharmaceuticals, Inc. (US:SUPN) valued at $47,239,129 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on May 27, 2026 disclosing 1,079,471 shares of Supernus Pharmaceuticals, Inc.. This represents a change in shares of -15.34% during the quarter. The current value of the position is $40,851,017 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 913,893 -165,578 -15.34 47,239 -11.95 0.0028
2026-05-27 2025-12-31 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 1,079,471 324,154 42.92 53,650 48.63 0.0032
2026-02-13 2025-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 1,079,471 324,154 53,650 0.0032
2026-05-27 2025-09-30 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 755,317 61,565 8.87 36,097 65.07 0.0022
2025-11-14 2025-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 755,317 61,565 36,097 0.0022
2025-08-15 2025-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 693,752 43,914 6.76 21,867 2.75 0.0014
2025-05-15 2025-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 649,838 -27,829 -4.11 21,282 -13.15 0.0015
2025-05-15 2024-12-31 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 677,667 -48,446 -6.67 24,504 8.23 0.0017
2025-02-14 2024-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 677,667 -48,446 24,504 0.0017
2025-05-14 2024-09-30 13F/A-2 SUPERNUS PHARMACEUTICALS COM 868459108 726,113 55,546 8.28 22,640 26.22 0.0016
2025-02-14 2024-09-30 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 726,113 55,546 22,640 0.0016
2024-11-14 2024-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 726,113 55,546 22,640 0.0002
2025-05-14 2024-06-30 13F/A-2 SUPERNUS PHARMACEUTICALS COM 868459108 670,567 20,341 3.13 17,938 -19.13 0.0014
2024-10-17 2024-06-30 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 670,567 20,341 17,938 0.0014
2024-08-14 2024-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 670,567 20,341 17,938 0.0014
2024-10-17 2024-03-31 13F/A-2 SUPERNUS PHARMACEUTICALS COM 868459108 650,226 -73,129 -10.11 22,179 5.95 0.0018
2024-08-16 2024-03-31 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 650,226 -73,129 22,179 0.0002
2024-05-15 2024-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 650,226 -73,129 22,179 0.0018
2024-08-16 2023-12-31 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 723,355 194,776 36.85 20,934 43.65 0.0018
2024-02-13 2023-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 723,355 194,776 20,934 0.0018
2023-11-15 2023-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 528,579 -27,319 -4.91 14,573 -12.79 0.0015
2023-08-14 2023-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 555,898 15,013 2.78 16,710 -14.73 0.0016
2023-05-15 2023-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 540,885 -189,558 -25.95 19,596 -24.79 0.0021
2023-02-14 2022-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 730,443 214,709 41.63 26,055 49.25 0.0030
2022-11-14 2022-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 515,734 41,705 8.80 17,457 27.33 0.0024
2022-10-27 2022-06-30 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 474,029 241,325 103.70 13,710 82.29 0.0018
2022-08-15 2022-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 474,029 241,325 13,710 0.0018
2022-10-27 2022-03-31 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 232,704 -45,348 -16.31 7,521 -7.25 0.0010
2022-05-13 2022-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 232,704 -45,348 7,521 0.0010
2022-02-14 2021-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 278,052 53,295 23.71 8,109 35.26 0.0010
2021-11-15 2021-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 224,757 -38,372 -14.58 5,995 -26.02 0.0008
2021-08-23 2021-06-30 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 263,129 68,458 35.17 8,103 58.98 0.0011
2021-08-16 2021-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 263,129 68,458 8,103 0.0002
2021-05-17 2021-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 194,671 -33,890 -14.83 5,097 -11.37 0.0007
2021-02-16 2020-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 228,561 -175,476 -43.43 5,751 -31.70 0.0009
2020-11-13 2020-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 404,037 -215,789 -34.81 8,420 -42.80 0.0016
2020-08-14 2020-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 619,826 -522,283 -45.73 14,720 -28.36 0.0033
2020-05-26 2020-03-31 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 1,142,109 67,945 6.33 20,546 -19.36 0.0056
2020-05-15 2020-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 1,142,109 67,945 20,546 1,578.3611
2020-02-14 2019-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 1,074,164 728,785 211.01 25,478 168.42 0.0059
2019-11-14 2019-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 345,379 24,106 7.50 9,492 -10.72 0.0025
2019-08-14 2019-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 321,273 -67,875 -17.44 10,632 -22.03 0.0028
2019-05-15 2019-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 389,148 -150,051 -27.83 13,636 -23.87 0.0039
2019-02-14 2018-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 539,199 151,411 39.04 17,912 -8.26 0.0054
2019-04-23 2018-09-30 13F/A-2 SUPERNUS PHARMACEUTICALS COM 868459108 387,788 -89,009 -18.67 19,524 -31.58 0.0049
2018-11-20 2018-09-30 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 387,788 0 19,524 0.0049
2018-11-14 2018-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 387,788 -89,009 19,524
2019-04-23 2018-06-30 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 476,797 263,559 123.60 28,537 192.21 0.0077
2018-08-14 2018-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 476,797 263,559 28,537
2019-04-23 2018-03-31 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 213,238 -13,508 -5.96 9,766 8.08 0.0027
2018-05-14 2018-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 213,238 -13,508 9,766
2019-04-23 2017-12-31 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 226,746 8,400 3.85 9,036 3.47 0.0025
2018-02-14 2017-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 226,746 8,400 9,036
2017-11-14 2017-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 218,346 -192,380 -46.84 8,733 -50.67 0.0026
2017-08-11 2017-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 410,726 61,451 17.59 17,702 61.93 0.0053
2017-05-22 2017-03-31 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 349,275 -160,556 -31.49 10,932 -15.08 0.0034
2017-05-12 2017-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 349,275 10,932
2017-02-22 2016-12-31 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 509,831 176,890 53.13 12,873 56.36 0.0042
2017-02-13 2016-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 509,831 12,873
2016-11-10 2016-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 332,941 -211,519 -38.85 8,233 -25.77 0.0028
2016-08-12 2016-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 544,460 -20,024 -3.55 11,091 28.85 0.0040
2016-05-12 2016-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 564,484 -11,610 -2.02 8,608 11.19 0.0033
2016-02-09 2015-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 576,094 138,608 31.68 7,742 26.13 0.0028
2016-02-08 2015-09-30 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 437,486 56,190 14.74 6,138 -5.19 0.0023
2015-11-09 2015-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 437,486 6,138
2015-08-12 2015-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 381,296 343,265 902.59 6,474 1,307.39 0.0022
2015-05-14 2015-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 38,031 -151,534 -79.94 460 -70.76 0.0002
2015-02-13 2014-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 189,565 134,992 247.36 1,573 231.16 0.0006
2014-12-16 2014-09-30 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 54,573 -251,304 -82.16 475 -82.63 0.0002
2014-11-14 2014-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 54,573 475
2014-05-13 2014-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 305,877 158,962 108.20 2,735 146.84 0.0011
2014-02-13 2013-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 146,915 87,541 147.44 1,108 154.71 0.0005
2013-11-13 2013-09-30 13F SUPERNUS PHARMACEUTICALS IN COM 868459108 59,374 -4,339 -6.81 435 6.10 0.0002
2013-08-08 2013-06-30 13F SUPERNUS PHARMACEUTICALS IN COM 868459108 63,713 63,713 410 0.0002
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.